Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06), Yahoo Finance reports. During the same quarter in the prior year, the company earned ($0.28) EPS.
Acumen Pharmaceuticals Price Performance
Acumen Pharmaceuticals stock traded down $0.34 during trading hours on Wednesday, reaching $2.43. 118,490 shares of the stock were exchanged, compared to its average volume of 383,895. The company has a current ratio of 30.20, a quick ratio of 30.20 and a debt-to-equity ratio of 0.12. Acumen Pharmaceuticals has a twelve month low of $1.81 and a twelve month high of $7.25. The company has a market cap of $145.99 million, a P/E ratio of -2.28 and a beta of 0.11. The stock has a 50 day moving average of $2.70 and a two-hundred day moving average of $3.29.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. Citigroup upgraded shares of Acumen Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a research report on Wednesday.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Recommended Stories
- Five stocks we like better than Acumen Pharmaceuticals
- What Do S&P 500 Stocks Tell Investors About the Market?
- Brinker International’s Price Dip is an Appetizing Entry Point
- Quiet Period Expirations Explained
- 3 Stocks That Could Beat the September Blues
- With Risk Tolerance, One Size Does Not Fit All
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.